Heat Biologics: Meet the team behind a robust COVID-19 vaccine

Heat Biologics Inc (NASDAQ:HTBX) is one of five biopharma companies presenting at Proactive’s online event on September 10 – all of them are playing a role to combat COVID-19. The event kicks off at 1 pm EDT on Thursday, September 10. This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses. SIGN-UP: Proactive One2One September 10, 1pm Heat Biologics, a clinical-stage biopharmaceutical, is developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine. Thursday’s presentation follows some promising preclinical results from a study of a potential vaccine based on its already-developed gp96 platform. A study found that Heat’s vaccine candidate “significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity that‘s essential against any viral infection, including SARS-CoV-2”, the virus that causes the COVID disease.  It elicits a robust immune response directed against the Spike protein of SARS-CoV-2. "We believe that these results are a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs,” said Jeff Wolf chief executive. The other companies on Thursday’s roster include AIM ImmunoTech Inc, Avalon GloboCare Corp (NASDAQ:AVCO), Oregenisis Inc (NASDAQ:ORGS), ImmunoPrecise Antibodies Ltd (CVE:IPA, OTCQB:IPATF).